0000000000217472

AUTHOR

Joëlle Micallef

showing 3 related works from this author

Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy

2021

Therapies - Sous presse. Epreuves corrigees par l'auteur. Disponible en ligne depuis le mardi 13 avril 2021

AdultMale2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19 vaccines030226 pharmacology & pharmacyArticle03 medical and health sciencesPharmacovigilance0302 clinical medicineBell's palsyPhase 3 clinical trialsBell PalsymedicineType I interferonsHumansBell's palsyPharmacology (medical)Potential mechanismComputingMilieux_MISCELLANEOUSAgedCOVID-19 coronavirus disease 2019Vaccines SyntheticMessenger RNASARS-CoV-2business.industryCOVID-19Bell’s palsyMiddle Agedmedicine.diseaseVirologymRNA messenger RNA3. Good healthInterferon Type IFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct

French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge.

2021

International audience; In this special issue, we present the main highlights of the first weeks of pharmacovigilance monitoring of coronavirus disease 2019 (COVID-19) vaccines in this unprecedented situation in France: the deployment of a vaccination during an epidemic period with the aim of vaccinating the entire population and the intense pharmacovigilance and surveillance of these vaccines still under conditional marketing authorizations. In this unprecedented situation, the cross approach and interaction between the French pharmacovigilance network and French National Agency for the Safety of Medicines and Health Products (ANSM) has been optimized to provide a real-time safety related …

MaleEuropean levelCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Adverse drug reactions030226 pharmacology & pharmacyArticleADR adverse drug reaction03 medical and health sciencesPharmacovigilance0302 clinical medicinePharmacovigilancePandemicMedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)Drug reactionPEG polyethylene glycolEntire populationVaccinesbusiness.industrySOC system organ classSARS-CoV-2COVID coronavirus disease[SCCO.NEUR]Cognitive science/Neuroscience[SCCO.NEUR] Cognitive science/NeuroscienceAuthorizationCOVID-19Middle Agedmedicine.diseaseRPVC Regional Pharmacovigilance CenterVaccinationEMA European Medicines AgencyFemaleMedical emergencyFrancebusinessANSM Agence nationale de sécurité du médicament et des produits de santé (French National Agency for the Safety of Medicines and Health Products)OrganizationTherapie
researchProduct

Atypical thrombosis associated with VaxZevria (R) (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres

2021

The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to s…

2019-20 coronavirus outbreakTime FactorsCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[SDV]Life Sciences [q-bio]Letter to EditorAntiviral AgentsPharmacovigilancePharmacovigilancemedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)PandemicsComputingMilieux_MISCELLANEOUSCovid-19 vaccineSARS-CoV-2business.industryCOVID-19VaxZevria®medicine.diseaseAtypical thrombosisThrombosisVirology[SDV] Life Sciences [q-bio]Anti-PF4 antibodiesFrancebusinessThrombopenia
researchProduct